Cellectar restates 2022-2024 financials; warrant accounting error triggers non-reliance

Cellectar Biosciences, Inc.

Board concludes FY2022, FY2023 audited and Q1-Q3 2023, Q1 2024 interim statements are unreliable.
Errors stem from accounting treatment of warrants issued in October 2022 financing.
Restatement required; company unable to estimate amount or effect at this time.
Filing of Q2 2024 Form 10-Q will be delayed pending restatement.
Discussed with current auditor Deloitte and former auditor Baker Tilly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.